MacroGenics, Inc. (MGNX)

From the record

MacroGenics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

MacroGenics, Inc.'s 10 filed years say what it did: revenue went from $92 million in fiscal 2016 to $150 million in fiscal 2025, up 5.6% a year; it rose in 5 of 9 years; the deepest fall was 63% from fiscal 2017 to fiscal 2023; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, MacroGenics, Inc. lost about 134 cents for every dollar of shareholders' money, and gross profitability: its products earned about 58 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 78 cents per dollar of assets, and net share issuance: its share count grew 0.9% over the year (the filed statements).

From the record

MacroGenics, Inc.'s standing among 315 graded names in its industry family: revenue of $150 million in fiscal 2025 ranks in the top 32% by size; a net margin of -49.9% ranks in the top 40%; revenue growth of -0.5% a year over the last 3 filed years ranks in the bottom 37% (its annual reports).

From the record

MacroGenics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Risser, Eric Blasius (President and CEO, as filed), filing under that title since 2025-08-15, 1.2 years (bottom 17% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 9.6 years (top 9%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (top 42%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

MacroGenics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $57 million against no long-term debt tagged leaves 22.3% of its assets as net cash, bottom 44% of its family; cash from operations less capital spending is -55.5% of revenue (top 45%); a gross margin of 100% (top 1%); research spending of 98.4% of revenue (bottom 49%) (its annual report).

From the record

MacroGenics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.5% a year over the last three filed years against 5.6% over all 10, slowing (bottom 42% of its family); the newest year grew -0.3% (bottom 36%); research spending grew -10.7% a year (bottom 29%); capital spending grew -19.2% a year (bottom 46%) (its annual reports). MacroGenics, Inc. reported 3 product lines in fiscal 2025: Revenue From Collaborative Agreements at $87 million (58%), Contract Manufacturing at $53 million (35%), Revenue From Royality Agreements at $10 million (7%); 2 of 3 grew against the year before (its annual report).

From the record

MacroGenics, Inc.'s newest year against its own record: revenue of $150 million in fiscal 2025 came in 0.3% above the $149 million its prior three years' pace pointed to (top 45% of its family); net income of $75 million against a prior three-year average of $65 million (bottom 36%); a net margin of -49.9% against -46.3% before (bottom 33%) (its annual reports).